ANI Pharma (ANIP) Tops Q4 EPS by 18c ; Offers Guidance

ANI Pharma (NASDAQ: ANIP) reported Q4 EPS of $1.63, $0.18 better than the analyst estimate of $1.45. Revenue for the quarter came in at $190.6 million versus the consensus estimate of $175.12 million.

GUIDANCE:

ANI Pharma sees FY2025 EPS of $6.12-$6.49, versus the consensus of $5.56. ANI Pharma sees FY2025 revenue of $756-776 million, versus the consensus of $724.9 million.

For earnings history and earnings-related data on ANI Pharma (ANIP) click here.

You May Also Be Interested In

• Benchmark Starts Boyd Gaming (BYD) at Buy
• SpaceX launches senior unsecured notes offering to repay bridge loan
• Ennis (EBF) Reports In-Line Q1 EPS